588 PATENT ABSTRACTS

oculation device useful by clinical laboratories in storing and transferring microorganisms to various growth media for testing or cell main- tenance programs.

5280112

D N A S E Q U E N C E E N C O D I N G B O V I N E A N D H U M A N

A D R E N O C O R T I C O T R O P I C H O R M O N E R E C E P T O R S

Roger D Cone, Kathleen G Mountjoy assigned to State of Oregon Oregon Health Sciences University

The present invention relates to a mammalian adrenocorticotropic hormone receptor. The in- vention is directed toward the isolation, charac- terization and pharmacological use of mammalian adrenocorticotropic hormone receptor, the gene corresponding to this recep- tor, a recombinant eukaryotic expression con- struct capable of expressing a mammalian adrenocorticotropic hormone receptor in cul- tures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that syn- thesize mammalian adrenocorticotropic hor- mone receptor. The invention also provides methods for screening ACTHR agonists and an- tagonists in vitro using preparations of receptor from such cultures of eukaryotic cells trans- formed with a recombinant eukaryotic expression construct comprising the ACTHR receptor gene. The invention specifically pro- vides human and bovine ACTHR genes.

5280113

M E T H O D F O R P R O D U C I N G S Y N T H E T I C N - L I N K E D G L Y C O C O N J U G A T E S

Thomas W Rademacher, lan D Manger, Simon Wong, Raymond A Dwek, Oxford, MO, United Kingdom assigned to Monsanto Company

A method is disclosed for derivatizing oligosac- charides to form synthetic N-linked glycocon- jugates by converting a glyeosylamine derivative of the oligosaccharide to a haloacetylated derivative as an intermediate compound prior to formation of the synthetic N-linked glycocon- jugate to thereby directly maintain the beta- anomeric configuration of said N-linked glycoconjugate.

5281417

A N T I T U M O R P R O C E S S E M P L O Y I N G N O V E L F E R M E N T A T E O F A N

A C T I N O M A D U R A S T R A I N

Daniel R Schroeder, Kin SLam, Jacqueline M Veitch assigned to Bristol-Myers Squibb Com- pany

A certain fermentation product of Ac- tinomadura strain Q473-8 yields, when suitably treated, a novel compound having both anti- biotic and antitumor activities.

5 ~ 1 4 ~

O S M O T I C C O N C E N T R A T I O N A P P A R A T U S A N D M E T H O D F O R

D I R E C T O S M O T I C C O N C E N T R A T I O N O F F R U I T

J U I C E S

John Herron, Edward G Beaudry, Carl Jochums, Luis Medina assigned to Osmotek Inc

There is disclosed an osmotic concentration cell wherein the flow chamber of the osmotic con- centration cell has a continually changing flow path to provide a region of high turbulence to a semipermeable membrane defining the flow chamber. High turbulence at a first semi- permeable membrane interface significantly reduces membrane fouling during osmotic con- centration and allows for concentration of pro- ducts with high suspended solids content. The inventive osmotic concentration cell can be used for a variety of purposes including, for example, producing low alcohol wine, concentrating a thin wine into a premium wine, concentrating a low quality grape juice into a higher quality grape juice for fermenting a more premium wine, concentrating various fruit or vegetable juices, and concentrating various beverages, such as teas or coffee.

5281516

T E M P E R A T U R E C O N T R O L A P P A R A T U S A N D M E T H O D

Marilyn Stapleton, Warren Jewett assigned to Gene Tec Corporation